Clinical development failure
Pipeline value depends on proving safety and efficacy in human studies.
- Scope
- SIM0505, LNCB74 and future candidates
- Materiality
- high
NextCure, Inc.
NextCure, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, including antibody-drug conjugates. Its pipeline includes SIM0505 and LNCB74, and the company also maintains a dedicated manufacturing facility to support clinical development.
4.14
4.14
| % | |
|---|---|
| Clinical-stage ADC programs | 70% Development of antibody-drug conjugate oncology candidates for patients with unmet need. |
| Licensed ADC platform technology | 20% Use of licensed ADC technology to develop additional proprietary antibody-based candidates. |
| Research and discovery platform | 10% Biology, biomarker, and tumor microenvironment research used to identify targets and candidates. |
NextCure does not currently sell commercial products; its work is directed toward future patients with cancer,...
- Future oncology patientsprimary
Patients with cancers that do not respond to current therapies; they are the intended beneficiaries of approved products.
- Clinical trial sites and investigatorsprimary
Hospitals and physicians that enroll patients and administer study protocols for SIM0505, LNCB74, and other candidates.
- Contract development and manufacturing organizationssecondary
Third parties that manufacture ADC intermediates and drug product or support clinical supply.
- Potential future healthcare providers and payorssecondary
Oncologists, hospitals, and insurers that would influence adoption and reimbursement after approval.
- Licensing and collaboration partnerssecondary
Partners that may provide upfront fees, development support, or commercialization rights in selected territories.
NextCure is headquartered in the United States and conducts its core research, development, and corporate activities...
- •Headquartered and primarily operated in the United States
- •Clinical development and corporate functions are U.S.-based
- •SIM0505 rights exclude China, Hong Kong, Macau, and Taiwan
- •Third-party manufacturing may involve non-U.S. facilities
- •Foreign regulatory and trade rules can affect CMO access
NextCure’s strategy is to advance SIM0505 and LNCB74 through clinical development and, if successful, toward regulatory...
01
Advance lead ADC programsshort-term
Clinical progress is the main value driver for a company without commercial revenue.
02
Secure additional fundingshort-term
Development programs require capital before any product revenue can be generated.
03
Preserve development optionalitymedium-term
Partnerships and licensing can broaden resources and reduce single-asset dependence.
04
Maintain manufacturing readinessmedium-term
ADC programs require reliable clinical supply and future commercial scalability.
NextCure faces the typical risks of a clinical-stage biotech company: no approved products, dependence on clinical...
Financing risk
The company has no product sales and must raise capital to continue operations.
- Scope
- Equity dilution, debt terms, partnership dependence
- Materiality
- high
Third-party manufacturing and trial execution
CROs and CDMOs control key steps in development and supply.
- Scope
- Clinical timelines, product supply, data quality
- Materiality
- high
Regulatory and healthcare compliance
Drug approval, promotion, and commercial arrangements are heavily regulated.
- Scope
- FDA review, anti-kickback and fraud-and-abuse rules
- Materiality
- medium
Foreign manufacturing and trade restrictions
Some manufacturing is tied to non-U.S. facilities and counterparties.
- Scope
- CMO access, supply continuity, geopolitical disruption
- Materiality
- medium
Clinical trial accruals
Can shift expense recognition between periods
Share-based compensation valuation
Affects G&A and R&D expense levels
Going-concern assessment
Important for liquidity disclosure and investor interpretation
No revenue recognition from product sales
Reported results are dominated by operating expenses and financing activity
: 29.4.2026